Apyx Medical Corporation to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Rhea-AI Summary

Apyx Medical (NASDAQ:APYX) said management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 10, 2026 in Snowbird, Utah.

Investors seeking meetings should contact their BTIG representatives. The company highlighted its Renuvion, J-Plasma, and FDA-cleared AYON Body Contouring System and noted more than 90 supporting clinical documents.

News Market Reaction – APYX

+1.00%

+1.00% Session close to close

In the Jan 29 session, APYX gained 1.00%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Apyx Medical’s participation in a major MedTech-focused conference on F...

Analysis

This announcement highlights Apyx Medical’s participation in a major MedTech-focused conference on February 10, 2026, offering management another venue to discuss its Renuvion and AYON platforms. Recent history includes revenue growth, international product approvals, and capital-raising activity, all shaping the company’s trajectory. Investors may watch how the conference presence complements earlier milestones, such as preliminary 2025 revenue results and AYON’s commercial rollout, within the broader medical devices landscape.

Key Figures

Clinical evidence base: more than 90 clinical documents Conference date: February 10, 2026

2 metrics

Clinical evidence base more than 90 clinical documents Supports effectiveness of Renuvion and J-Plasma

Conference date February 10, 2026 BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Historical Context

5 past events · Latest: Jan 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 12	Prelim revenue update	Positive	+14.9%	Preliminary Q4 and full-year 2025 revenue showing double-digit growth momentum.
Dec 03	Intl product launch	Positive	-1.7%	MFDS approval and launch of Apyx One console for cosmetic procedures in South Korea.
Nov 18	Equity offering priced	Negative	-5.5%	Underwritten public offering of common stock for about $10M gross proceeds.
Nov 17	Equity offering proposed	Negative	+3.3%	Announcement of proposed underwritten public offering from an effective Form S-3 shelf.
Nov 06	Quarterly earnings	Positive	+6.7%	Q3 2025 results with revenue growth, margin improvement, and raised full-year guidance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Across the last five news events, three price reactions aligned with the apparent sentiment and two diverged, with offerings and commercial updates drawing mixed responses.

Recent Company History

Over recent months, Apyx highlighted revenue growth and product expansion. On Nov 6, 2025, Q3 2025 results showed rising revenue and improved margins, and the stock reacted positively. In Nov 2025, proposed and priced equity offerings under a shelf registration led to mixed share responses. A preliminary Q4 and full-year 2025 revenue update on Jan 12, 2026 was followed by a strong gain. Today’s conference participation fits into an ongoing cadence of operational and investor-facing updates.

Key Terms

helium plasma platform technology, electrosurgical, fda-cleared

3 terms

helium plasma platform technology medical

"including its Helium Plasma Platform Technology products marketed and sold as Renuvion"

A helium plasma platform uses a stream of ionized helium gas energized by radiofrequency energy to heat, cut or seal human tissue during surgical and aesthetic procedures. Think of it as a focused, high‑heat tool that lets clinicians tighten skin, remove tissue, or control bleeding with minimal cutting—similar to a precision blowtorch compared with a scalpel. Investors care because the technology’s safety profile, regulatory approvals, and adoption by doctors drive device sales, recurring disposable use and potential market growth.

electrosurgical medical

"integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion"

Electrosurgical describes tools and procedures that use controlled electric current to cut, seal, or stop bleeding in body tissues during medical procedures, similar to using a heated knife or a precise spark instead of a scalpel. For investors, electrosurgical products matter because they drive sales, device adoption, regulatory reviews, and liability risk in the surgical devices market—factors that affect revenue, profit margins, and company valuations.

fda-cleared regulatory

"The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CLEARWATER, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion^® and the AYON Body Contouring System™ (AYON), today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 10, 2026 in Snowbird, Utah.

To request a meeting with Apyx, investors should contact their BTIG representatives.

About Apyx Medical Corporation:

Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion^® and the AYON Body Contouring System^TM in the cosmetic surgery market and J-Plasma^® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

Investor Relations Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com

FAQ

When will Apyx Medical (APYX) present at the BTIG conference?

Apyx Medical management will participate on February 10, 2026 in Snowbird, Utah. According to Apyx Medical, investors who want meetings should contact their BTIG representatives to request a slot ahead of the conference.

How can investors request a meeting with Apyx Medical (APYX) at the BTIG event?

Investors should contact their BTIG representative to request a meeting with Apyx Medical. According to Apyx Medical, BTIG handles scheduling and will coordinate investor meetings with company management prior to the February 10, 2026 conference.

What Apyx Medical products will be highlighted relating to the BTIG 2026 participation?

Apyx Medical highlighted Renuvion, J-Plasma, and the AYON Body Contouring System as core products. According to Apyx Medical, AYON is FDA-cleared and the company cites more than 90 clinical documents supporting Renuvion and J-Plasma effectiveness.

Is the AYON Body Contouring System FDA-cleared as mentioned by Apyx Medical (APYX)?

Yes, the AYON Body Contouring System is described as FDA-cleared by Apyx Medical. According to Apyx Medical, AYON combines fat removal, closed-loop contouring, electrosurgical capabilities, and Renuvion for tissue contraction in an all-in-one platform.

Does Apyx Medical (APYX) cite clinical support for Renuvion and J-Plasma in the announcement?

Apyx Medical states there are more than 90 clinical documents supporting Renuvion and J-Plasma effectiveness. According to Apyx Medical, these documents underpin the surgical uses of its Helium Plasma Platform across cosmetic and hospital markets.